Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 1/20 | 0.41 |
| ▸ | RXRB | P28702 | 1/20 | 0.41 |
| ▸ | RXRG | P48443 | 1/20 | 0.41 |
| ▸ | ATR | Q13535 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CYP4F2 | P78329 | 5/20 | 0.37 |
| ▸ | CYP4A11 | Q02928 | 5/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | RET | P07949 | 1/20 | 0.35 |
| ▸ | ELANE | P08246 | 3/20 | 0.34 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.34 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.34 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.34 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.33 |
| ▸ | AR | P10275 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22499151 | 0.89 | RXRA (0.40) | RXRARXRBRXRGATRALDH1A1 | |
| SCHEMBL806439 | 0.85 | ATR (0.40) | RXRARXRBRXRGATRALDH1A1 | |
| SCHEMBL22499058 | 0.85 | RXRA (0.41) | RXRARXRBRXRGATRALDH1A1 | |
| SCHEMBL5019990 | 0.83 | RXRA (0.39) | RXRARXRBRXRGATRALDH1A1 | |
| SCHEMBL25242455 | 0.82 | RXRA (0.42) | RXRARXRBRXRGATRALDH1A1 | |
| SCHEMBL30444945 | 0.82 | RXRA (0.42) | RXRARXRBRXRGATRALDH1A1 | |
| SCHEMBL4223412 | 0.82 | ALDH1A1 (0.42) | RXRARXRBRXRGATRALDH1A1 | |
| SCHEMBL156398 | 0.82 | RXRA (0.42) | RXRARXRBRXRGALDH1A1LMNA | |
| SCHEMBL168052 | 0.82 | DDB1 (0.51) | RXRARXRBRXRGATRALDH1A1 | |
| SCHEMBL4572292 | 0.82 | CYP4F2 (0.46) | RXRARXRBRXRGATRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388577-A1 | METTL3 INHIBITORY COMPOUNDS | STORM THERAPEUTICS LTD (GB) | 2025-12-25 | — | — | US | disclosed |
| US-12358915-B2 | METTL3 inhibitory compounds | STORM Therapeutics Ltd. (GB) | 2025-07-15 | — | — | US | disclosed |
| US-20250122195-A1 | POLYHETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS | STORM THERAPEUTICS LIMITED (GB) | 2025-04-17 | — | — | US | disclosed |
| US-12195458-B2 | Polyheterocyclic compounds as METTL3 inhibitors | STORM THERAPEUTICS LIMITED (GB) | 2025-01-14 | — | — | US | disclosed |
| US-11725010-B2 | Polyheterocyclic compounds as METTL3 inhibitors | STORM THERAPEUTICS LIMITED (GB) | 2023-08-15 | — | — | US | disclosed |
| US-11725010-B2 | Polyheterocyclic compounds as METTL3 inhibitors | STORM THERAPEUTICS LIMITED (GB) | 2023-08-15 | — | — | US | disclosed |
| US-11725010-B2 | Polyheterocyclic compounds as METTL3 inhibitors | STORM THERAPEUTICS LIMITED (GB) | 2023-08-15 | — | — | US | disclosed |
| US-20230116403-A1 | POLYHETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS | EVOTEC INTERNATIONAL GMBH (DE) | 2023-04-13 | — | — | US | disclosed |
| US-20230085408-A1 | METTL3 INHIBITORY COMPOUNDS | STORM THERAPEUTICS LIMITED (GB) | 2023-03-16 | — | — | US | disclosed |
| US-20230002378-A1 | POLYHETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS | STORM THERAPEUTICS LIMITED (GB) | 2023-01-05 | — | — | US | disclosed |
| EP-3946618-A1 | METTL3 INHIBITORY COMPOUNDS | Storm Therapeutics Ltd (GB) | 2022-02-09 | — | — | EP | disclosed |
| CN-113905787-A | METTL3 inhibiting compounds | 斯托姆治疗有限公司 | 2022-01-07 | — | — | CN | disclosed |
| WO-2021111124-A1 | POLYHETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS | STORM THERAPEUTICS LIMITED (GB) | 2021-06-10 | — | — | WO | disclosed |
| WO-2021111124-A1 | POLYHETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS | STORM THERAPEUTICS LIMITED (GB) | 2021-06-10 | — | — | WO | disclosed |
| WO-2020201773-A1 | METTL3 INHIBITORY COMPOUNDS | STORM THERAPEUTICS LTD (GB) | 2020-10-08 | — | — | WO | disclosed |
| WO-2020201773-A1 | METTL3 INHIBITORY COMPOUNDS | STORM THERAPEUTICS LTD (GB) | 2020-10-08 | — | — | WO | disclosed |
| EP-2748159-A1 | SERINE/THREONINE PAK1 INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2014-07-02 | — | — | EP | disclosed |
| US-8637537-B2 | Serine/threonine kinase inhibitors | GENENTECH, INC. (US) | 2014-01-28 | — | — | US | disclosed |
| US-20130225620-A1 | SERINE/THREONINE KINASE INHIBITORS | GENENTECH, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| WO-2013026914-A1 | SERINE/THREONINE PAK1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12358915-B2 | METTL3 inhibitory compounds | METTL3, METTL16, DIMT1 | RXRA 3680/4885RXRB 3424/4885RXRG 3482/4885 |
| US-20250122195-A1 | POLYHETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS | METTL3, DIMT1, TPMT | RXRA 3584/4885RXRB 3449/4885RXRG 3445/4885 |
| US-20230002378-A1 | POLYHETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS | METTL3, DIMT1, TPMT | RXRA 3584/4885RXRB 3449/4885RXRG 3445/4885 |
| US-20250388577-A1 | METTL3 INHIBITORY COMPOUNDS | METTL3, RNMT, TPMT | RXRA 3396/4885RXRB 2830/4885RXRG 3139/4885 |
| US-20230116403-A1 | POLYHETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS | METTL3, DIMT1, TPMT | RXRA 3584/4885RXRB 3449/4885RXRG 3445/4885 |
| US-11725010-B2 | Polyheterocyclic compounds as METTL3 inhibitors | METTL3, DIMT1, TPMT | RXRA 3584/4885RXRB 3449/4885RXRG 3445/4885 |
| US-12195458-B2 | Polyheterocyclic compounds as METTL3 inhibitors | METTL3, DIMT1, TPMT | RXRA 3584/4885RXRB 3449/4885RXRG 3445/4885 |
| US-20130225620-A1 | SERINE/THREONINE KINASE INHIBITORS | PAK1, AKT1, RB1 | RXRA 1879/4885RXRB 1556/4885RXRG 2253/4885 |
| US-20230085408-A1 | METTL3 INHIBITORY COMPOUNDS | METTL3, METTL16, DIMT1 | RXRA 3680/4885RXRB 3424/4885RXRG 3482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.